Table 2.
Univariable and Multivariable Analysis for OS
| Characteristics | UVA | P Value | MVA | P Value |
|---|---|---|---|---|
| Age at diagnosis | 1.02 (1.01–1.03) | <.001 | 1.00 (0.99–1.02) | .39 |
| KPS | 0.97 (0.96–0.98) | <.001 | 0.98 (0.97–0.99) | .001 |
| Male sex | 1.03 (0.82–1.21) | .78 | — | — |
| Non-White race | 1.07 (0.65–1.77) | .80 | — | — |
| mGBM (vs hGBM) | 0.68 (0.40–1.17) | .16 | 0.50 (0.29–0.88) | .02 |
| Extent of resection | ||||
| GTR | Ref | |||
| STR | 1.56 (1.18–2.06) | .002 | 1.66 (1.24–2.22) | .001 |
| Biopsy | 3.264 (2.42–4.40) | <.001 | 3.05 (2.22–4.17) | <.001 |
| Unmethylated MGMT | 1.79 (1.39–2.30) | <.001 | 1.81 (1.40–2.35) | <.001 |
| HFRT | 2.48 (1.83–3.37) | <.001 | 1.53 (1.04–2.24) | .03 |
| No TMZ chemotherapy | 2.68 (1.86–3.85) | <.001 | 1.61 (1.07–2.41) | .02 |
| TERT mutation (n = 184) | 1.14 (0.64–2.03) | .67 | — | — |
| EGFR amplification by FISH or NGS (n = 277) | 1.21 (0.92–1.58) | .18 | — | — |
| CDKN2A/B deletion by NGS (n = 150) | 1.46 (0.96–2.21) | .08 | — | — |
| Pathways affected | — | — | ||
| Three pathways | Ref | |||
| Two pathways | 0.71 (0.33–1.53) | .38 | ||
| One pathway | 0.32 (0.08–1.28) | .11 |
FISH, fluorescence in situ hybridization; GTR, gross-total/near-total resection; HFRT, short-course hypofractionated radiation therapy; hGBM, histological GBM; mGBM, molecular glioblastoma; MVA, multivariable analysis; NGS, next-generation sequencing; STR, subtotal resection; TMZ, temozolomide; UVA, univariable analysis.